An oncologist is reflecting on the rising interest in advanced cancer detection methods, such as whole-body MRI scans and multi-cancer blood tests. While these tests can identify cancer at an early stage, they are still considered investigational and are not recommended for the general public. The American College of Radiology has stated there is not enough evidence to support the use of whole-body MRI scans for people without symptoms or high-risk conditions. There is also no clear proof that these scans prolong life or are cost-effective. A review of over 5,000 people without symptoms found that about one-third of whole-body MRI scans revealed incidental findings—some of which were critical or unclear. Many of these findings turned out to be false positives, meaning they were not actual cancer cases. This uncertainty has led experts to classify the scans as investigational, as there is limited data on their real-world effectiveness. Actress Busy Philipps has drawn attention to this debate after undergoing a whole-body Prenuvo MRI, which detected a malignant brain tumor. Philipps acknowledged her "inherent privilege" in being able to afford the scan, which costs nearly $3,100. Her experience highlights the dilemma many face when considering such tests—some may feel the potential benefits outweigh the risks, especially if traditional screening methods fall short. However, oncologists warn that for most people, these tests can lead to unnecessary procedures, additional costs, and emotional distress. Multi-cancer blood tests, such as GRAIL’s Galleri test, are also under discussion. This test analyzes methylation patterns in DNA to detect potential cancer signals. However, it is not a definitive diagnosis and requires further testing if a positive result is found. A negative result does not eliminate the possibility of cancer and does not replace standard screenings like mammograms or colonoscopies. Although the Galleri test is available for purchase, it has not received FDA approval and costs $949. A large British trial showed some positive results, including fewer late-stage diagnoses for certain deadly cancers, but it did not meet its main goal of reducing late-stage cancer detection. The increasing rate of cancer among younger adults has raised concerns about the effectiveness of current screening methods. Colorectal cancer rates among Americans under 49 are rising by about 3 percent annually, and around 83,000 Americans aged 20 to 39 are diagnosed with cancer each year. These numbers have led some to question whether more advanced tests may offer better protection. However, oncologists stress that decisions about undergoing such tests should be made with a clear understanding of both their potential benefits and risks. The high cost of these advanced tests has raised concerns about creating a two-tier system in cancer prevention, where only those who can afford them gain access to more information. Meanwhile, many patients struggle to obtain basic, life-saving screenings that are already known to be effective. According to the American Cancer Society, at least 40 percent of newly diagnosed cancers in adults could have been potentially prevented. For example, the HPV vaccine can prevent over 90 percent of HPV-related cancers, yet less than two-thirds of young adults in the U.S. were up to date on their vaccinations in 2024. Similarly, only about one-third of adults aged 45 to 49 received the recommended colorectal cancer screenings. The oncologist concludes that while people should not be denied access to emerging cancer detection tests, they must be given clear information about the tests’ FDA status, the populations they were studied on, the frequency of false positives, the follow-up needed, and whether they have been shown to reduce cancer deaths. Companies offering these tests should also explain how results will be interpreted, what next steps are required, and how costs will be managed. Doctors have a responsibility to address the fear behind such requests by thoroughly reviewing a patient’s family history, risk factors, vaccinations, and whether standard screenings are up to date. While some patients may still choose to pay for an investigational test, they should do so with a realistic understanding of both its potential value and its possible harms.